In a move that has baseball fans buzzing, the Baltimore Orioles have brought back Zach Eflin, re-signing the right-handed pitcher to a one-year deal worth $10 million, according to reports from USA Today’s Bob Nightengale and The New York Post’s Jon Heyman. But here’s where it gets intriguing: the contract includes a mutual option for 2027, as noted by Andy Kostka of the Baltimore Banner, adding a layer of flexibility for both the team and the player. Eflin, represented by O’Connell Sports Management, is no stranger to the Orioles, but his return comes with a twist—his health has been a question mark since undergoing back surgery in August, with a recovery timeline of 4-8 months. Could this signing be a high-reward gamble for Baltimore?
The Orioles have been making waves this offseason, not just with Eflin’s return but also with their recent trade for Shane Baz, a pitcher with frontline potential. While Baz represents a bold move for the top of the rotation, Eflin’s role is more about depth, serving as a reliable arm for the back end. However, his health remains the elephant in the room. The fact that he’s signed just four months after surgery suggests his rehab is progressing well, but will he be ready for Opening Day? If so, it’s a win-win for both Eflin and the Orioles, who could use his experience and skill. And this is the part most people miss: Eflin’s return could be a critical piece in Baltimore’s puzzle as they aim to strengthen their pitching staff for the upcoming season.
But let’s not shy away from the controversy: Is this a smart move for the Orioles, or are they taking an unnecessary risk on a player with injury concerns? With top-tier free agents and trades already in the mix, does Eflin’s signing truly move the needle? Weigh in below—do you think this was a strategic addition or a risky bet? More updates are sure to come as the Orioles continue to shape their roster, but for now, Eflin’s return is a story worth watching closely.
